E H Ohlstein
Overview
Explore the profile of E H Ohlstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
164
Citations
2276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Behm D, McAtee J, Dodson J, Neeb M, Fries H, Evans C, et al.
Br J Pharmacol
. 2008 Jul;
155(3):374-86.
PMID: 18587423
Background And Purpose: The recent development of the UT ligand palosuran (1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulphate salt) has led to the proposition that urotensin-II (U-II) plays a significant pathological role in acute and...
2.
Yue Tl T, Chen J, Bao W, Narayanan P, Bril A, Jiang W, et al.
Circulation
. 2001 Nov;
104(21):2588-94.
PMID: 11714655
Background: Diabetes is associated with increased risk of mortality as a consequence of acute myocardial infarction. This study determined whether rosiglitazone (ROSI) could reduce myocardial infarction after ischemia/reperfusion injury. Methods...
3.
Willette R, Anderson K, Nelson A, Olzinski A, Woods T, Coatney R, et al.
J Cardiovasc Pharmacol
. 2001 Oct;
38(4):606-17.
PMID: 11588531
Evidence suggests that endothelin receptor antagonists may have therapeutic potential for the chronic treatment of heart failure. In the current study, the effects of an orally active mixed endothelin-A/endothelin-B (ETA...
4.
Behr T, Nerurkar S, Nelson A, Coatney R, Woods T, Sulpizio A, et al.
Circulation
. 2001 Sep;
104(11):1292-8.
PMID: 11551882
Background: Numerous pathological mediators of cardiac hypertrophy (eg, neurohormones, cytokines, and stretch) have been shown to activate p38 MAPK. The purpose of the present study was to examine p38 MAPK...
5.
Shaw M, Shennib H, Bousette N, Ohlstein E, Giaid A
Ann Thorac Surg
. 2001 Aug;
72(2):386-90.
PMID: 11515871
Background: It is postulated that apoptosis contributes to ischemia-reperfusion graft dysfunction after lung transplantation. The purpose of this study was to determine whether the improvement in lung function that we...
6.
Romanic A, Burns-Kurtis C, Ao Z, Arleth A, Ohlstein E
Am J Physiol Renal Physiol
. 2001 Jul;
281(2):F309-17.
PMID: 11457723
Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that degrade the extracellular matrix (ECM). The membrane-type matrix metalloproteinases (MT-MMPs) are a new family of MMPs that differ from other...
7.
Erhardt J, Ohlstein E, Toomey J, Gabriel M, Willette R, Yue T, et al.
Thromb Res
. 2001 Jul;
103(2):143-8.
PMID: 11457472
No abstract available.
8.
Barone F, Coatney R, Chandra S, Sarkar S, Nelson A, Contino L, et al.
Cardiovasc Res
. 2001 May;
50(3):525-37.
PMID: 11376628
Objective: Eprosartan is a selective angiotensin II type I receptor antagonist approved for the treatment of hypertension. In the present studies, eprosartan's ability to provide end-organ protection was evaluated in...
9.
Emery J, Ohlstein E, Jaye M
Trends Pharmacol Sci
. 2001 May;
22(5):233-40.
PMID: 11339974
Aberrant gene expression is a fundamental cause of many disease-associated pathophysiologies. The pharmacological modulation of transcription factor activity therefore represents an attractive therapeutic approach to such disorders. With the exception...
10.
Douglas S, Ohlstein E
Trends Cardiovasc Med
. 2001 Apr;
10(6):229-37.
PMID: 11282300
The novel cyclic undecapeptide human urotensin-II (hU-II) and its high-affinity G-protein-coupled receptor, GPR14, are both expressed within the human cardiovasculature (vascular smooth muscle, endothelium, myocardium, coronary atheroma, etc.) and may,...